JOP20200014A1 - توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf - Google Patents
توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط rafInfo
- Publication number
- JOP20200014A1 JOP20200014A1 JOP/2020/0014A JOP20200014A JOP20200014A1 JO P20200014 A1 JOP20200014 A1 JO P20200014A1 JO P20200014 A JOP20200014 A JO P20200014A JO P20200014 A1 JOP20200014 A1 JO P20200014A1
- Authority
- JO
- Jordan
- Prior art keywords
- inhibitor
- tyrosine kinase
- combination
- egfr tyrosine
- generation egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بتوليفة صيدلانية تشتمل على (أ) مثبط كيناز تيروزين EGFR من الجيل الثالث و(ب) مثبط Raf، تحديداً لعلاج السرطان، تحديداً سرطان رئة. يتعلق الاختراع الحالي أيضاً باستخدامات تلك التوليفة لتحضير دواء لعلاج سرطان؛ بطرق لعلاج سرطان في كائن بحاجة لذلك تشمل إعطاء الكائن المذكور كمية فعّالة علاجياً بصورة مشتركة من التوليفة المذكورة؛ بتركيبات صيدلانية تشمل تلك التوليفة وبعبوات تجارية لها.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762540595P | 2017-08-03 | 2017-08-03 | |
PCT/IB2018/055792 WO2019026007A1 (en) | 2017-08-03 | 2018-08-01 | THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200014A1 true JOP20200014A1 (ar) | 2022-10-30 |
Family
ID=63405289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0014A JOP20200014A1 (ar) | 2017-08-03 | 2018-08-01 | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf |
Country Status (18)
Country | Link |
---|---|
US (1) | US20200237773A1 (ar) |
EP (1) | EP3661516A1 (ar) |
JP (1) | JP2020529411A (ar) |
KR (1) | KR20200036880A (ar) |
CN (1) | CN110996960A (ar) |
AU (1) | AU2018311523A1 (ar) |
BR (1) | BR112020001916A2 (ar) |
CA (1) | CA3069564A1 (ar) |
CL (1) | CL2020000270A1 (ar) |
IL (1) | IL272350A (ar) |
JO (1) | JOP20200014A1 (ar) |
MX (1) | MX2020001254A (ar) |
PH (1) | PH12020500096A1 (ar) |
RU (1) | RU2020108192A (ar) |
SG (1) | SG11201913249SA (ar) |
TW (1) | TW201909920A (ar) |
WO (1) | WO2019026007A1 (ar) |
ZA (1) | ZA201908392B (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115701996A (zh) * | 2020-06-25 | 2023-02-14 | 托雷莫治疗股份公司 | 用于治疗EGFR突变型NSCLC的CBP/p300溴结构域抑制剂和EGFR抑制剂的组合 |
CN111991559B (zh) * | 2020-09-03 | 2022-03-22 | 中山大学 | 受体酪氨酸激酶抑制剂在制备预防和/或治疗新型冠状病毒感染药物中的应用 |
WO2023141659A2 (en) * | 2022-01-24 | 2023-07-27 | The Trustees Of Columbia University In The City Of New York | Targeting s100a9-aldh1a1-retinoic acid signaling to suppress brain relapse in egfr-mutant lung cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
PL2882440T3 (pl) * | 2012-08-07 | 2019-07-31 | Novartis Ag | Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa |
US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2018
- 2018-08-01 SG SG11201913249SA patent/SG11201913249SA/en unknown
- 2018-08-01 CN CN201880050143.XA patent/CN110996960A/zh active Pending
- 2018-08-01 EP EP18760056.4A patent/EP3661516A1/en not_active Withdrawn
- 2018-08-01 WO PCT/IB2018/055792 patent/WO2019026007A1/en unknown
- 2018-08-01 MX MX2020001254A patent/MX2020001254A/es unknown
- 2018-08-01 RU RU2020108192A patent/RU2020108192A/ru not_active Application Discontinuation
- 2018-08-01 CA CA3069564A patent/CA3069564A1/en not_active Abandoned
- 2018-08-01 AU AU2018311523A patent/AU2018311523A1/en not_active Abandoned
- 2018-08-01 BR BR112020001916-0A patent/BR112020001916A2/pt not_active Application Discontinuation
- 2018-08-01 KR KR1020207004658A patent/KR20200036880A/ko unknown
- 2018-08-01 JP JP2020505209A patent/JP2020529411A/ja active Pending
- 2018-08-01 US US16/634,924 patent/US20200237773A1/en not_active Abandoned
- 2018-08-01 JO JOP/2020/0014A patent/JOP20200014A1/ar unknown
- 2018-08-03 TW TW107127150A patent/TW201909920A/zh unknown
-
2019
- 2019-12-17 ZA ZA2019/08392A patent/ZA201908392B/en unknown
-
2020
- 2020-01-14 PH PH12020500096A patent/PH12020500096A1/en unknown
- 2020-01-29 IL IL272350A patent/IL272350A/en unknown
- 2020-01-30 CL CL2020000270A patent/CL2020000270A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2020529411A (ja) | 2020-10-08 |
RU2020108192A (ru) | 2021-09-03 |
EP3661516A1 (en) | 2020-06-10 |
MX2020001254A (es) | 2020-03-20 |
TW201909920A (zh) | 2019-03-16 |
US20200237773A1 (en) | 2020-07-30 |
KR20200036880A (ko) | 2020-04-07 |
BR112020001916A2 (pt) | 2020-07-28 |
CL2020000270A1 (es) | 2020-08-28 |
PH12020500096A1 (en) | 2020-09-14 |
CA3069564A1 (en) | 2019-02-07 |
AU2018311523A1 (en) | 2020-01-16 |
SG11201913249SA (en) | 2020-02-27 |
CN110996960A (zh) | 2020-04-10 |
WO2019026007A1 (en) | 2019-02-07 |
ZA201908392B (en) | 2021-05-26 |
IL272350A (en) | 2020-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
MX2019001920A (es) | Arn la terapia contra el cancer. | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
PH12018500642A1 (en) | Anti-garp antibody | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
WO2016109217A3 (en) | Btk inhibitors | |
PH12016502353A1 (en) | Pharmaceutical composition | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
MX2019003134A (es) | Terapia de combinacion. | |
TW201613577A (en) | Pharmaceutical combinations | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. |